{"schema_version":"secwatch.filing_event.v1","accession":"0001326190-23-000020","form_type":"8-K","ticker":"ALT","cik":"0001326190","company_name":"Altimmune, Inc.","filed_at":"2023-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.420354+00:00","generated_at":"2026-06-17T14:34:24.009536+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Altimmune appoints former GSK executive Catherine Sohn to board of directors","bullets":["Catherine Sohn, Pharm.D., appointed to Altimmune's Board effective March 23, 2023.","Dr. Sohn currently serves on boards of Jazz Pharma, Axcellea Health, and Maze Therapeutics.","She was formerly SVP Worldwide Business Development at GSK's Consumer Healthcare division.","Received initial option award for 47,000 shares and annual cash retainer of $40,000.","CEO Vipin Garg says her experience in peptide therapeutics for obesity and liver disease will be valuable."],"urls":{"canonical":"https://secwatch.observer/filing/0001326190-23-000020","json":"https://secwatch.observer/filing/0001326190-23-000020.json","markdown":"https://secwatch.observer/filing/0001326190-23-000020.md","text":"https://secwatch.observer/filing/0001326190-23-000020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326190/000132619023000020/0001326190-23-000020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326190/000132619023000020/alt-20230323x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T14:34:24.009536+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1497701315","claim":"Catherine Sohn was appointed as Director at Altimmune, Inc..","evidence_excerpt":"appointed Catherine Sohn, Pharm.D. as a director of the Company’s Board, effective March 23, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326190/000132619023000020/0001326190-23-000020-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}